Suppr超能文献

在英国,年龄相关性黄斑变性导致的视力丧失负担有多大?

How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?

作者信息

Owen C G, Fletcher A E, Donoghue M, Rudnicka A R

机构信息

Department of Public Health Sciences, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK.

出版信息

Br J Ophthalmol. 2003 Mar;87(3):312-7. doi: 10.1136/bjo.87.3.312.

Abstract

AIMS

To predict the burden of blindness, partial sight, and visual impairment (binocular visual acuity 6/18 or less) due to late stage age related macular degeneration (AMD) in the ageing population of the United Kingdom.

METHODS

A systematic review, followed by a request for data, was used to establish a pooled prevalence of AMD and corresponding visual loss. Prevalence figures were applied to the UK population. Using UK population trends, the future burden of AMD over the coming decade was established.

RESULTS

Pooled data from six studies showed that the prevalence of visual loss caused by AMD increased exponentially from the age of 70-85 years of age, with 3.5% (95% CI 3.0 to 4.1) having visual impairment beyond the age of 75 years. The authors estimate that there are currently 214 000 (95% CI 151 000 to 310 000) with visual impairment caused by AMD (suitable for registration). This number is expected to increase to 239 000 (95% CI 168 000 to 346 000) by the year 2011. Currently there are 172 000 (95% CI 106 000 to 279 000) and 245 000 (95% CI 163 000 to 364 000) with geographical and neovascular AMD, respectively.

CONCLUSIONS

Estimates of visual impairment agree with official statistics for the number registered partially sighted or blind, caused by AMD, and are well below other figures often cited. Although these estimates are associated with wide confidence intervals (CI) and a number of caveats, they represent the best available data, which can be used to guide health and social care provision for older people in the UK setting. Implications for low vision services are outlined.

摘要

目的

预测英国老年人群中因晚期年龄相关性黄斑变性(AMD)导致的失明、视力部分丧失及视力损害(双眼视力6/18或更低)的负担。

方法

通过系统综述并随后索取数据,以确定AMD的合并患病率及相应的视力丧失情况。将患病率数据应用于英国人口。利用英国人口趋势,确定未来十年AMD的负担情况。

结果

六项研究的汇总数据显示,由AMD导致的视力丧失患病率在70至85岁年龄段呈指数增长,75岁以上人群中有3.5%(95%置信区间3.0至4.1)存在视力损害。作者估计,目前有214000例(95%置信区间151000至310000)因AMD导致视力损害(适合登记)。预计到2011年,这一数字将增至239000例(95%置信区间168000至346000)。目前,分别有172000例(95%置信区间106000至279000)和245000例(95%置信区间163000至364000)患有地图样萎缩性和新生血管性AMD。

结论

视力损害的估计与AMD导致的部分视力受损或失明登记人数的官方统计数据一致,且远低于其他经常引用的数字。尽管这些估计存在较宽的置信区间(CI)及一些限制条件,但它们代表了现有最佳数据,可用于指导英国老年人群的健康和社会护理服务提供。概述了对低视力服务的影响。

相似文献

2
Implantable miniature telescope (IMT) for vision loss due to end-stage age-related macular degeneration.
Cochrane Database Syst Rev. 2018 May 30;5(5):CD011140. doi: 10.1002/14651858.CD011140.pub2.
3
Community screening for visual impairment in older people.
Cochrane Database Syst Rev. 2018 Feb 20;2(2):CD001054. doi: 10.1002/14651858.CD001054.pub3.
4
Reading aids for adults with low vision.
Cochrane Database Syst Rev. 2018 Apr 17;4(4):CD003303. doi: 10.1002/14651858.CD003303.pub4.
5
Blue-light filtering intraocular lenses (IOLs) for protecting macular health.
Cochrane Database Syst Rev. 2018 May 22;5(5):CD011977. doi: 10.1002/14651858.CD011977.pub2.
6
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
8
Vision screening for correctable visual acuity deficits in school-age children and adolescents.
Cochrane Database Syst Rev. 2018 Feb 15;2(2):CD005023. doi: 10.1002/14651858.CD005023.pub3.
9
Community views on mass drug administration for soil-transmitted helminths: a qualitative evidence synthesis.
Cochrane Database Syst Rev. 2025 Jun 20;6:CD015794. doi: 10.1002/14651858.CD015794.pub2.
10
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.

引用本文的文献

1
Neoteric Role of Quercetin in Visual Disorders.
Curr Drug Res Rev. 2024;16(2):164-174. doi: 10.2174/2589977515666230822114324.
2
Blue-light filtering spectacle lenses for visual performance, sleep, and macular health in adults.
Cochrane Database Syst Rev. 2023 Aug 18;8(8):CD013244. doi: 10.1002/14651858.CD013244.pub2.
7
8
Patient-reported outcome measures in the management of neovascular age-related macular degeneration: a 1-year prospective study.
BMJ Open Ophthalmol. 2019 Oct 3;4(1):e000353. doi: 10.1136/bmjophth-2019-000353. eCollection 2019.
9
Inflammatory Ocular Diseases and Sphingolipid Signaling.
Adv Exp Med Biol. 2019;1159:139-152. doi: 10.1007/978-3-030-21162-2_8.

本文引用的文献

1
2
Risk factors for age-related macular degeneration: Pooled findings from three continents.
Ophthalmology. 2001 Apr;108(4):697-704. doi: 10.1016/s0161-6420(00)00580-7.
3
Extracts from "clinical evidence": age related macular degeneration.
BMJ. 2000 Sep 23;321(7263):741-4. doi: 10.1136/bmj.321.7263.741.
4
The prevalence of age-related maculopathy: the visual impairment project.
Ophthalmology. 2000 Aug;107(8):1593-600. doi: 10.1016/s0161-6420(00)00175-5.
5
Helping blind and partially sighted people to read: the effectiveness of low vision aids.
Br J Ophthalmol. 2000 Aug;84(8):919-21. doi: 10.1136/bjo.84.8.919.
7
Prospective study of alcohol consumption and the risk of age-related macular degeneration.
Arch Ophthalmol. 2000 May;118(5):681-8. doi: 10.1001/archopht.118.5.681.
8
Age-specific causes of bilateral visual impairment.
Arch Ophthalmol. 2000 Feb;118(2):264-9. doi: 10.1001/archopht.118.2.264.
9
Genetic susceptibility to age related macular degeneration.
J Med Genet. 2000 Feb;37(2):83-7. doi: 10.1136/jmg.37.2.83.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验